- Home
- ZBIO vs VYGR Comparison
ZBIO vs VYGR Comparison
Compare ZBIO & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBIO
- VYGR
- Stock Information
- Founded
- ZBIO 2019
- VYGR 2013
- Country
- ZBIO United States
- VYGR United States
- Employees
- ZBIO N/A
- VYGR N/A
- Industry
- ZBIO
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- ZBIO
- VYGR Health Care
- Exchange
- ZBIO NYSE
- VYGR Nasdaq
- Market Cap
- ZBIO 339.3M
- VYGR 342.5M
- IPO Year
- ZBIO 2024
- VYGR 2015
- Fundamental
- Price
- ZBIO $8.40
- VYGR $5.22
- Analyst Decision
- ZBIO Strong Buy
- VYGR Strong Buy
- Analyst Count
- ZBIO 5
- VYGR 9
- Target Price
- ZBIO $31.75
- VYGR $15.53
- AVG Volume (30 Days)
- ZBIO 371.9K
- VYGR 361.6K
- Earning Date
- ZBIO 02-16-2025
- VYGR 02-26-2025
- Dividend Yield
- ZBIO N/A
- VYGR N/A
- EPS Growth
- ZBIO N/A
- VYGR N/A
- EPS
- ZBIO N/A
- VYGR 0.47
- Revenue
- ZBIO N/A
- VYGR $163,784,000.00
- Revenue This Year
- ZBIO N/A
- VYGR N/A
- Revenue Next Year
- ZBIO N/A
- VYGR N/A
- P/E Ratio
- ZBIO N/A
- VYGR $11.19
- Revenue Growth
- ZBIO N/A
- VYGR 3.40
- 52 Week Low
- ZBIO $7.50
- VYGR $4.99
- 52 Week High
- ZBIO $26.25
- VYGR $10.66
- Technical
- Relative Strength Index (RSI)
- ZBIO N/A
- VYGR 38.79
- Support Level
- ZBIO N/A
- VYGR $4.99
- Resistance Level
- ZBIO N/A
- VYGR $5.45
- Average True Range (ATR)
- ZBIO 0.00
- VYGR 0.26
- MACD
- ZBIO 0.00
- VYGR -0.05
- Stochastic Oscillator
- ZBIO 0.00
- VYGR 17.97
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.